Search

Displaying results 1501 - 1510 of 10000 in total
  1. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.

  2. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529]. … Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    Reduction in testosterone is important in treating men with advanced prostate cancer. … FDA approved on December 24, 2008.

  4. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35677] It was FDA approved on July 20, 2018.[L3770]

  5. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication.

  6. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

    Categories: Drugs Used in Erectile Dysfunction
  7. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.

  8. Drug

    Trimethadione

    go.drugbank.com/drugs/DB00347
    ApprovedWithdrawn

    An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

  9. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    FDA approved on July 26, 2012. … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.

    Synonyms: E-EPA
  10. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive … Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in